The US has approved the first treatment to redesign a patient’s own immune system so it attacks cancer. The regulator – the US Food and Drug Administration – said its decision was a “historic” moment and medicine was now “entering a new frontier”. The company Novartis is charging $475,000 (£367,000) for the “living drug” therapy, which leaves 83% of people free of a type of blood cancer. Doctors in the UK said the announcement was an exciting step forward. The living drug is tailor-made to each patient, unlike conventional therapies…
Read MoreFirst cancer ‘living drug’ gets go-ahead
